Compare SLE & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLE | MSLE |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | Canada |
| Employees | 34 | N/A |
| Industry | Services-Misc. Amusement & Recreation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.4M | 154.6M |
| IPO Year | 2019 | 2007 |
| Metric | SLE | MSLE |
|---|---|---|
| Price | $3.86 | $8.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 19.0K |
| Earning Date | 05-14-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,064,000.00 | N/A |
| Revenue This Year | $24.86 | N/A |
| Revenue Next Year | $49.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 90.41 | N/A |
| 52 Week Low | $0.48 | $5.44 |
| 52 Week High | $11.43 | $13.39 |
| Indicator | SLE | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 51.49 |
| Support Level | $2.89 | $9.10 |
| Resistance Level | $4.89 | $10.22 |
| Average True Range (ATR) | 0.83 | 0.43 |
| MACD | 0.02 | -0.13 |
| Stochastic Oscillator | 33.52 | 21.74 |
Super League Enterprise Inc connects brands with the gaming population of around 3.5 billion through advertising and branded content programs across gaming and digital media platforms. The Company generates revenue by delivering these programs through proprietary interactive formats, creator content, immersive experiences, data-driven insights, and strategic campaign services designed to improve marketing performance. By translating player behavior into actionable intelligence, Super League serves as a trusted partner helping brands reach and influence consumers who play video games. With a deep understanding of this engaged yet under-monetized audience, it is positioned to capture an increasing share of brand advertising spend as the market evolves.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.